Wolf Haldenstein Announces Investigation Of Sarepta Therapeutics, Inc.,

Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities that purchased the securities of Sarepta Therapeutics, Inc., (NASDAQ:SRPT) between July 24, 2013 and November 12, 2013.

The complaint alleges that during the Class Period, certain of the Company’s officers and directors violated federal securities laws by making false and misleading statements concerning the Company’s lead therapeutic candidate for the treatment of Duchenne muscular dystrophy, eteplirsen.

Specifically, the Complaint alleges that multiple misleading statements were made concerning: (1) the prospects of the Food and Drug Administration's ("FDA") acceptance for consideration of a New Drug Application ("NDA") for eteplirsen based on Sarepta's Phase IIb study data set, and (2) the significance of the Phase IIb data set.

On November 12, 2013, Sarepta disclosed that the FDA informed the Company that its announced NDA filing for eteplirsen was premature. On this news, Sarepta's stock price collapsed from its closing price of $36.56 per share on November 11, 2013 to $13.16 per share on November 12, 2013.

If you purchased Sarepta common stock during the Class Period, you may, no later than March 28, 2014, request that the Court appoint you as lead plaintiff of the class.

If you are a shareholder of Sarepta Therapeutics, Inc., (NASDAQ:SRPT) with a loss of $75,000 or more and would like additional information concerning your rights in this matter, please contact us at:

Gregory M. Nespole or Patrick DonovanWolf Haldenstein Adler Freeman & Herz LLP270 Madison AvenueNew York, New York 10016

Phone Numbers:(800) 575-0735(212) 545-4600

Please visit the Wolf Haldenstein website ( http://www.whafh.com) for more information about the firm.

Wolf Haldenstein did not file the original complaint against Sarepta Therapeutics, Inc.

Email:

If you liked this article you might like

Sarepta Therapeutics Chart Patterns Look Good

Verastem Shares Are Exploding 50% -- Here's Why

Watch the Key Technical Levels

Net Seller, but Itching to Put More Cash to Work